Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma
- PMID: 16596244
Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma
Abstract
Cholangiocarcinoma development may be related to cholangiocyte DNA damage from genotoxic compounds in bile. We have previously shown that human biliary tissue is exposed to genotoxic agents, as evidenced by the presence of DNA adducts. Establishing the presence of a 'mutational signature' in tumour suppressor genes from tumour tissue provides a means of linking cause and effect in human cancer. Inactivation of p53, known to have 'hot-spots' for particular chemical carcinogens, has previously been linked to human cholangiocarcinoma. However, previous p53 studies have focused on exons 5-8, potentially missing gene alterations at other sites. This study examined the putative link between environmental carcinogens and intrahepatic cholangiocarcinoma by analysing DNA from 31 patients for complete p53 mutational signatures, using single strand conformational polymorphism and polymerase chain reaction. All mutations found were compared to known p53 mutations in cholangiocarcinoma and to mutations induced by environmental mutagens, as described in p53 databases. Five non-silent p53 mutations were found, including three new frameshift mutations and two new intron mutations which have not previously been reported in cholangiocarcinoma. Two frameshifts were due to deletions and the third due to an insertion in exon 5. There was no predominant mutational spectrum amongst the set of cholangiocarcinoma samples studied, or on combining these mutations with the dataset of known p53 mutations in cholangiocarcinoma. Several reasons may explain this, including lack of data outside exons 5-8, bias in mutation reporting, the involvement of mutations in non-coding regions or genes other than p53, or the possibility that there is no carcinogenic specific agent and therefore no signature.
Similar articles
-
p53 Mutations in human cholangiocarcinoma: a review.Liver Int. 2005 Aug;25(4):704-16. doi: 10.1111/j.1478-3231.2005.01106.x. Liver Int. 2005. PMID: 15998419 Review.
-
K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients.Southeast Asian J Trop Med Public Health. 1998 Mar;29(1):71-5. Southeast Asian J Trop Med Public Health. 1998. PMID: 9740272
-
Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.Lab Invest. 1999 Apr;79(4):477-83. Lab Invest. 1999. PMID: 10212000
-
Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer.Cancer Res. 2002 Aug 1;62(15):4331-8. Cancer Res. 2002. PMID: 12154037
-
Role of epigenetic alterations in cholangiocarcinoma.J Hepatobiliary Pancreat Surg. 2006;13(4):274-9. doi: 10.1007/s00534-005-1055-3. J Hepatobiliary Pancreat Surg. 2006. PMID: 16858537 Review.
Cited by
-
Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development.Cancers (Basel). 2022 Mar 11;14(6):1442. doi: 10.3390/cancers14061442. Cancers (Basel). 2022. PMID: 35326593 Free PMC article. Review.
-
Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility.Oncol Lett. 2012 Jul;4(1):101-106. doi: 10.3892/ol.2012.680. Epub 2012 Apr 17. Oncol Lett. 2012. PMID: 22807971 Free PMC article.
-
Genome-wide single nucleotide polymorphism array analysis reveals recurrent genomic alterations associated with histopathologic features in intrahepatic cholangiocarcinoma.Int J Clin Exp Pathol. 2014 Sep 15;7(10):6841-51. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25400767 Free PMC article.
-
p53-dependent delayed effects of radiation vary according to time of irradiation of p53 + / - mice.J Radiat Res. 2014 Jan 1;55(1):25-31. doi: 10.1093/jrr/rrt083. Epub 2013 Jun 13. J Radiat Res. 2014. PMID: 23764457 Free PMC article.
-
Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers.J Oncol. 2013;2013:170625. doi: 10.1155/2013/170625. Epub 2013 Dec 18. J Oncol. 2013. PMID: 24454372 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous